Dehydrocostus Lactone Effectively Alleviates Inflammatory Diseases by Covalently and Irreversibly Targeting NLRP3

Abstract

The activation of nucleotide oligomerization domain-like receptor (NLR) family, pyrin domain-containing protein 3 (NLRP3) inflammasome is implicated in the pathogenesis of various inflammatory diseases. The natural product oridonin possesses a novel mechanism for NLRP3 inhibition and a unique binding mode with NLRP3, but its poor anti-inflammatory activity limits further application. After virtual screening of diverse natural product libraries, dehydrocostus lactone (DCL) was considered as a potential NLRP3 inhibitor. DCL effectively inhibited caspase-1 cleavage and release of IL-1β in mouse and human macrophages at an extremely low concentration of 10 nM, comparable to MCC950. Mechanistically, our study assigned DCL a novel role in disrupting NLRP3 inflammasome assembly and ASC oligomerization. Excluding the influence on potassium/chloride ion efflux, calcium ion influx, and production of mitochondrial ROS, DCL formed a covalent bond with cysteine 280 in NACHT domain of NLRP3, thereby inhibiting the interaction between NLRP3 and NEK7. Furthermore, DCL exhibited protective effects in mouse models of NLRP3 inflammasome-mediated diseases, including dextran sulfate sodium-induced colitis, 2,4,6-trinitrobenzenesulfonic acid-induced Crohn's disease, LPS-induced septic shock, and monosodium urate-induced peritonitis. Our findings identify NLRP3 as the direct target of DCL, positioning DCL as a promising lead compound for treatment of NLRP3 inflammasome-related diseases.

Keywords

covalent irreversible / cysteine 280 / dehydrocostus lactone / NLRP3 inflammasome / NLRP3-driven diseases

References

[1] H. Zhao, L. Wu, G. Yan, et al., “Inflammation and Tumor Progression: Signaling Pathways and Targeted Intervention,” Signal Transduction and Targeted Therapy 6, no. 1 (2021): 263.

[2] A. Hooftman, S. Angiari, S. Hester, et al., “The Immunomodulatory Metabolite Itaconate Modifies NLRP3 and Inhibits Inflammasome Activation,” Cell Metabolism 32, no. 3 (2020): 468-478.

[3] Y. Zhen and H. Zhang, “NLRP3 Inflammasome and Inflammatory Bowel Disease,” Frontiers in Immunology 10 (2019): 276.

[4] J. H. Ma, E. Lee, S. H. Yoon, et al., “Therapeutic Effect of NLRP3 Inhibition on Hearing Loss Induced by Systemic Inflammation in a CAPS-Associated Mouse Model,” EBioMedicine 82 (2022): 104184.

[5] Q. Li, Y. Zhao, H. Guo, et al., “Impaired Lipophagy Induced-microglial Lipid Droplets Accumulation Contributes to the Buildup of TREM1 in Diabetes-Associated Cognitive Impairment,” Autophagy 19, no. 10 (2023): 2639-2656.

[6] H. He, H. Jiang, Y. Chen, et al., “Oridonin is a Covalent NLRP3 Inhibitor With Strong Anti-Inflammasome Activity,” Nature Communications 9, no. 1 (2018): 2550.

[7] P. Kong, Z. Y. Cui, X. F. Huang, D. D. Zhang, R. J. Guo, and M. Han, “Inflammation and Atherosclerosis: Signaling Pathways and Therapeutic Intervention,” Signal Transduction and Targeted Therapy 7, no. 1 (2022): 131.

[8] Y. H. Youm, K. Y. Nguyen, R. W. Grant, et al., “The Ketone Metabolite β-Hydroxybutyrate Blocks NLRP3 Inflammasome-Mediated Inflammatory Disease,” Nature Medicine 21, no. 3 (2015): 263-269.

[9] Y. Huang, H. Jiang, Y. Chen, et al., “Tranilast Directly Targets NLRP3 to Treat Inflammasome-Driven Diseases,” EMBO Molecular Medicine 10, no. 4 (2018): e8689.

[10] H. Jiang, H. He, Y. Chen, et al., “Identification of a Selective and Direct NLRP3 Inhibitor to Treat Inflammatory Disorders,” Journal of Experimental Medicine 214, no. 11 (2017): 3219-3238.

[11] A. Tapia-Abellán, D. Angosto-Bazarra, H. Martínez-Banaclocha, et al., “MCC950 closes the Active Conformation of NLRP3 to an Inactive State,” Nature Chemical Biology 15, no. 6 (2019): 560-564.

[12] I. V. Hochheiser, M. Pilsl, G. Hagelueken, et al., “Structure of the NLRP3 Decamer Bound to the Cytokine Release Inhibitor CRID3,” Nature 604, no. 7904 (2022): 184-189.

[13] R. C. Coll, A. A. Robertson, J. J. Chae, et al., “A Small-Molecule Inhibitor of the NLRP3 Inflammasome for the Treatment of Inflammatory Diseases,” Nature Medicine 21, no. 3 (2015): 248-255.

[14] C. Dempsey, A. Rubio Araiz, K. J. Bryson, et al., “Inhibiting the NLRP3 Inflammasome With MCC950 Promotes Non-Phlogistic Clearance of Amyloid-β and Cognitive Function in APP/PS1 Mice,” Brain, Behavior, and Immunity 61 (2017): 306-316.

[15] D. V. Parmar, K. A. Kansagra, T. Momin, et al., “Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the Oral NLRP3 Inflammasome Inhibitor ZYIL1: First-in-Human Phase 1 Studies (Single Ascending Dose and Multiple Ascending Dose),” Clinical Pharmacology in Drug Development 12, no. 2 (2023): 202-211.

[16] L. Wang, J. Cai, X. Zhao, et al., “Palmitoylation Prevents Sustained Inflammation by Limiting NLRP3 Inflammasome Activation Through Chaperone-Mediated Autophagy,” Molecular Cell 83, no. 2 (2023): 281-297.

[17] J. Fu and H. Wu, “Structural Mechanisms of NLRP3 Inflammasome Assembly and Activation,” Annual Review of Immunology 41 (2023): 301-316.

[18] S. Zheng, X. Que, S. Wang, et al., “ZDHHC5-Mediated NLRP3 Palmitoylation Promotes NLRP3‒NEK7 Interaction and Inflammasome Activation,” Molecular Cell 83, no. 24 (2023): 4570-4585.

[19] Q. Lv, Y. Xing, J. Liu, et al., “Lonicerin Targets EZH2 to Alleviate Ulcerative Colitis by Autophagy-Mediated NLRP3 Inflammasome Inactivation,” Acta Pharmaceutica Sinica B 11, no. 9 (2021): 2880-2899.

[20] J. H. Liu, C. H. Hsieh, C. Y. Liu, C. W. Chang, Y. J. Chen, and T. H. Tsai, “Anti-Inflammatory Effects of Radix Aucklandiae Herbal Preparation Ameliorate Intestinal Mucositis Induced by 5-Fluorouracil in Mice,” Journal of Ethnopharmacology 271 (2021): 113912.

[21] Y. Xiong, X. Cui, Y. Zhou, et al., “Dehydrocostus Lactone Inhibits BLM-Induced Pulmonary Fibrosis and Inflammation in Mice via the JNK and p38 MAPK-Mediated NF-κB Signaling Pathways,” International Immunopharmacology 98 (2021): 107780.

[22] B. Hu, F. Wu, Z. Shi, et al., “Dehydrocostus Lactone Attenuates Osteoclastogenesis and Osteoclast-Induced Bone Loss by Modulating NF-κB Signalling Pathway,” Journal of Cellular and Molecular Medicine 23, no. 8 (2019): 5762-5770.

[23] Y. Chen, R. Li, Z. Wang, et al., “Dehydrocostus Lactone Inhibits NLRP3 Inflammasome Activation by Blocking ASC Oligomerization and Prevents LPS-Mediated Inflammation in Vivo,” Cellular Immunology 349 (2020): 104046.

[24] L. Kaly, M. Rozenbaum, D. Rimar, et al., “Ulcerative Colitis and Familial Mediterranean Fever: Can Anakinra Treat Both?,” ACG Case Reports Journal 6, no. 7 (2019): e00143.

[25] F. De Benedetti, M. Gattorno, and J. Anton, “Canakinumab for the Treatment of Autoinflammatory Recurrent Fever Syndromes,” New England Journal of Medicine 378, no. 20 (2018): 1908-1919.

[26] E. Tabor, “Phase 3 Trial of Interleukin-1 Trap Rilonacept in Recurrent Pericarditis,” New England Journal of Medicine 384, no. 15 (2021): 1474.

[27] H. Y. Chiang, H. H. Lu, J. N. Sudhakar, et al., “IL-22 Initiates an IL-18-Dependent Epithelial Response Circuit to Enforce Intestinal Host Defence,” Nature Communications 13, no. 1 (2022): 874.

[28] K. L. Winthrop, X. Mariette, and J. T. Silva, “ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the Safety of Targeted and Biological Therapies: An Infectious Diseases Perspective (Soluble Immune Effector Molecules [II]: Agents Targeting Interleukins, Immunoglobulins and Complement Factors),” Clinical Microbiology and Infection 24 (2018): S21-S40.

[29] Y. Yang, J. Zhang, C. Yang, et al., “Sulforaphane Attenuates Microglia-Mediated Neuronal Damage by Down-Regulating the ROS/Autophagy/NLRP3 Signal Axis in Fibrillar Aβ-Activated Microglia,” Brain Research 1801 (2023): 148206.

[30] A. J. Greaney, N. K. Maier, S. H. Leppla, and M. Moayeri, “Sulforaphane Inhibits Multiple Inflammasomes Through an Nrf2-Independent Mechanism,” Journal of Leukocyte Biology 99, no. 1 (2016): 189-199.

[31] K. Wang, Q. Lv, Y. M. Miao, S. M. Qiao, Y. Dai, and Z. F. Wei, “Cardamonin, a Natural Flavone, Alleviates Inflammatory Bowel Disease by the Inhibition of NLRP3 Inflammasome Activation via an AhR/Nrf2/NQO1 Pathway,” Biochemical Pharmacology 155 (2018): 494-509.

[32] C. L. Lamb, G. N. Cholico, X. Pu, G. D. Hagler, K. A. Cornell, and K. A. Mitchell, “2,3,7,8-Tetrachlorodibenzo-p-Dioxin (TCDD) Increases Necroinflammation and Hepatic Stellate Cell Activation but Does Not Exacerbate Experimental Liver Fibrosis in Mice,” Toxicology and Applied Pharmacology 311 (2016): 42-51.

[33] E. L. Goldberg, J. L. Asher, R. D. Molony, et al., “β-Hydroxybutyrate Deactivates Neutrophil NLRP3 Inflammasome to Relieve Gout Flares,” Cell Reports 18, no. 9 (2017): 2077-2087.

[34] R. C. Coll, J. R. Hill, C. J. Day, et al., “MCC950 directly Targets the NLRP3 ATP-Hydrolysis Motif for Inflammasome Inhibition,” Nature Chemical Biology 15, no. 6 (2019): 556-559.

[35] H. Li, Y. Guan, B. Liang, et al., “Therapeutic Potential of MCC950, a Specific Inhibitor of NLRP3 Inflammasome,” European Journal of Pharmacology 928 (2022): 175091.

[36] K. Sun, J. Wang, Z. Lan, et al., “Sleeve Gastroplasty Combined With the NLRP3 Inflammasome Inhibitor CY-09 Reduces Body Weight, Improves Insulin Resistance and Alleviates Hepatic Steatosis in Mouse Model,” Obesity Surgery 30, no. 9 (2020): 3435-3443.

[37] L. Boike, N. J. Henning, and D. K. Nomura, “Advances in Covalent Drug Discovery,” Nature Reviews Drug Discovery 21, no. 12 (2022): 881-898.

[38] H. Kim, Y. S. Hwang, M. Kim, and S. B. Park, “Recent Advances in the Development of Covalent Inhibitors,” RSC Medicinal Chemistry 12, no. 7 (2021): 1037-1045.

[39] T. A. Baillie, “Targeted Covalent Inhibitors for Drug Design,” Angewandte Chemie (International ed in English) 55, no. 43 (2016): 13408-13421.

[40] D. Schaefer and X. Cheng, “Recent Advances in Covalent Drug Discovery,” Pharmaceuticals (Basel) 16, no. 5 (2023): 663.

RIGHTS & PERMISSIONS

2025 The Author(s). MedComm published by Sichuan International Medical Exchange & Promotion Association (SCIMEA) and John Wiley & Sons Australia, Ltd.